{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T16:10:08Z","timestamp":1745511008240,"version":"3.40.4"},"reference-count":9,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.1182\/blood.2025028442","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:32:02Z","timestamp":1745508722000},"page":"1831-1832","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Beyond conVENtional 7+3 in acute myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-9595","authenticated-orcid":false,"given":"Christine M.","family":"McMahon","sequence":"first","affiliation":[{"name":"University of Colorado School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"17","key":"2025042411315673700_bib1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2025042411315673700_bib2","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer\u00a0Chemother Rep"},{"issue":"7","key":"2025042411315673700_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2025042411315673700_bib4","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025042411315673700_bib5","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2025042411315673700_bib6","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025042411315673700_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2024-203459","article-title":"A phase II trial of venetoclax in combination with cladribine, idarubicin, and cytarabine in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome [abstract]","volume":"144","author":"Bouligny","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025042411315673700_bib8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025042411315673700_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood-2024-199267","article-title":"Venetoclax plus azacitidine for newly diagnosed younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy [abstract]","volume":"144","author":"Watts","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1831\/2370310\/blood_bld-2025-028442-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1831\/2370310\/blood_bld-2025-028442-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:32:05Z","timestamp":1745508725000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/17\/1831\/536781\/Beyond-conVENtional-7-3-in-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":9,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025028442","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}